 Arbutus Biopharma NASDAQ: ABUS reported Q2 sales of 1.51 million. Earnings fell to a loss of 13.03 million, resulting in a 0.08 decrease from last quarter. In Q1, Arbutus Biopharma brought in 1.49 million in sales but lost 13.04 million in earnings.Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a companys ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Arbutus Biopharma posted an ROCE of -0.2.Keep in mind, while ROCE is a good measure of a companys recent performance, it is not a highly reliable predictor of a companys earnings or sales in the near future.View more earnings on ABUSROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Arbutus Biopharma is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will lead to higher returns and earnings per share growth.In Arbutus Biopharmas case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q2 Earnings Recap Arbutus Biopharma reported Q2 earnings per share at -0.25share, which did not meet analyst predictions of -0.24share.See more from Benzinga Recap: Arbutus Biopharma Q2 Earnings Earnings Scheduled For August 7, 2020 Stocks That Hit 52-Week Highs On FridayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 